Acquisition will advance Merck’s integrated offering for viral vector manufacturing

此次收购将推动默克公司为病毒载体制造提供集成服务

Complements existing portfolio for development and production of novel modalities such as cell and gene therapies

补充了现有的开发和生产新模式（如细胞和基因疗法）的组合

Novel modalities are a key growth area for Merck’s Life Science business sector

新型模式是默克生命科学业务部门的关键增长领域

Merck, a leading science and technology company, has signed a definitive agreement to acquire life science company Mirus Bio for US$ 600 million (around € 550 million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents. Transfection reagents, such as Mirus Bio's TransIT-VirusGEN®, are used to help introduce genetic material into cells.

领先的科技公司默克公司（Merck）已签署最终协议，以6亿美元（约5.5亿欧元）收购生命科学公司Mirus Bio。Mirus Bio位于美国威斯康星州麦迪逊，是转染试剂开发和商业化的专家。转染试剂，如Mirus Bio的TransIT VirusGEN®，用于帮助将遗传物质引入细胞。

These reagents play a key role in the production of viral vectors for cell and gene therapies..

这些试剂在细胞和基因治疗病毒载体的生产中起着关键作用。。

“This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future. As a leader in the production of viral vectors, our goal is to make the significant potential of cell and gene therapy available for patients worldwide,” said Belén Garijo, Chair of the Executive Board and CEO of Merck.

默克公司执行董事会主席兼首席执行官贝伦·加里霍（Belén Garijo）表示：“这项战略性收购是加速未来突破性技术增长的进一步基石。作为病毒载体生产的领导者，我们的目标是为全球患者提供细胞和基因治疗的巨大潜力。”。

“As a leading science and technology company, we are well-positioned to support our Life Science customers across the biopharmaceutical industry to bring new curative treatments to market.”.

“作为一家领先的科技公司，我们处于有利地位，可以支持生物制药行业的生命科学客户将新的治疗方法推向市场。”。

“Novel modalities, such as viral vector-based cell and gene therapies, hold immense promise to improve the lives of patients. Combining Mirus Bio's leading technology with Merck's bioprocessing expertise and portfolio allows us to provide solutions for almost every step of viral vector development and manufacturing,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science.

默克公司执行董事会成员、生命科学首席执行官马蒂亚斯·海因泽尔（MatthiasHeinzel）表示：“基于病毒载体的细胞和基因疗法等新型疗法有望改善患者的生活。将Mirus Bio的领先技术与默克公司的生物加工专业知识和产品组合相结合，使我们能够为病毒载体开发和制造的几乎每一步提供解决方案。”。

“With our integrated offering along the viral vector value chain, we are now well-positioned to support our customers in this fast-growing market to positively impact the lives and health of patients worldwide.”.

“凭借我们在病毒载体价值链上的集成服务，我们现在处于有利地位，可以在这个快速增长的市场中支持我们的客户，从而对全球患者的生活和健康产生积极影响。”。

“We have been driving innovation in nucleic acid delivery for two decades,” said Dale Gordon, CEO of Mirus Bio. “Merck’s broad portfolio, scale, and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide.”.

Mirus Bio首席执行官戴尔·戈登（Dale Gordon）表示：“二十年来，我们一直在推动核酸输送方面的创新。默克（Merck）广泛的投资组合、规模和全球影响力，加上我们领先的转染试剂，将有助于将我们的业务提升到更高的水平，并使我们能够为全球更多的客户，最终是患者提供服务。”。

The transaction with Gamma Biosciences, a life sciences platform established by global investment firm KKR, for the acquisition of Mirus Bio is expected to close in the third quarter of 2024 and is subject to regulatory clearance and other customary closing conditions.

与全球投资公司KKR建立的生命科学平台Gamma Biosciences进行的收购Mirus Bio的交易预计将于2024年第三季度完成，并需要监管部门的批准和其他惯例的关闭条件。

Merck’s Life Science business sector provides the tools, high-grade chemicals and consumables that accelerate scientific breakthroughs across the entire pharmaceutical industry. This includes one of the broadest product portfolios for bioproduction processes. The acquisition of Mirus Bio is an important step towards Merck's ambition to offer solutions for every step of viral vector manufacturing to advance cell and gene therapies from preclinical through commercial production.

默克的生命科学业务部门提供工具、高级化学品和消耗品，加速整个制药行业的科学突破。这包括生物生产过程中最广泛的产品组合之一。收购Mirus Bio是默克公司为病毒载体制造的每一步提供解决方案的重要一步，以促进细胞和基因治疗从临床前到商业生产。

The company’s expertise covers a variety of viral vector types, including adeno-associated virus, lentivirus, and adenovirus. Additionally, Merck offers both contract testing services and a wide range of comprehensive contract development and manufacturing services for viral vector manufacturing with more than three decades of experience supporting cell and gene therapies on the path to commercialization..

该公司的专业知识涵盖多种病毒载体类型，包括腺相关病毒、慢病毒和腺病毒。此外，默克公司为病毒载体制造提供合同测试服务和广泛的综合合同开发和制造服务，拥有三十多年的支持细胞和基因治疗商业化的经验。。

Novel Modalities like cell and gene therapies, antibody-drug conjugates or mRNA hold immense promise to improve the lives of patients. The global market for process products for these modalities is expected to grow by around 20% per year over the mid-term. For example, the overall number of cell and gene therapies in development has doubled since 2019, and more advance to commercial stage.

细胞和基因疗法，抗体-药物偶联物或mRNA等新型方式有望改善患者的生活。预计这些模式的全球加工产品市场在中期内每年将增长约20%。例如，自2019年以来，正在开发的细胞和基因疗法的总数翻了一番，并进一步进入商业阶段。

Viral Vectors play a key role in the production of these life-changing therapies. To support this growth, Merck opened its second Carlsbad, California-based viral vector contract development manufacturing facility in 2021. The € 100 million investment more than doubled the company’s capacity to support large-scale commercial and industrial manufacturing for viral gene therapy.

病毒载体在这些改变生命的疗法的生产中起着关键作用。为了支持这一增长，默克公司于2021年在加利福尼亚州卡尔斯巴德开设了第二家病毒载体合同开发制造工厂。这项1亿欧元的投资使该公司支持病毒基因治疗大规模商业和工业生产的能力翻了一番多。

Merck also invests in R&D to enable its customers to bring new curative treatments to market. In 2024, the company laid the cornerstone for a new Life Science research center at its global headquarters in Darmstadt. The more than € 300 million investment will bring together research on key technologies, including viral vectors and novel modalities like mRNA..

默克还投资研发，使其客户能够将新的治疗方法推向市场。2024年，该公司在达姆施塔特的全球总部为新的生命科学研究中心奠定了基础。这项超过3亿欧元的投资将汇集关键技术的研究，包括病毒载体和mRNA等新型模式。。